Role of biomarkers in community-acquired pneumonia management
Yükleniyor...
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wolters Kluwer
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Community-acquired pneumonia (CAP) poses a significant global health threat, particularly affecting vulnerable populations. Biomarkers and scoring systems play a crucial role in diagnosing, assessing severity, and guiding treatment decisions for CAP patients. Biomarkers like C reactive protein, procalcitonin, and the neutrophil-to-lymphocyte ratio aid in diagnosis and severity assessment, while scoring systems such as CURB-65 and Pneumonia Severity Index classify patients into risk categories. Emerging biomarkers (uremia, elevated respiratory rate, hypotension, and age ≥ 65) like serum amyloid A and S100 proteins show promise in predicting disease severity and prognosis. However, further research is needed to determine their precise roles and clinical utility in CAP management.
Açıklama
Anahtar Kelimeler
CURB-65, Community-Acquired Pneumonia, Procalcitonin, Alpha-1 Antitrypsin, Serum Amyloid A
Kaynak
Journal of Acute Disease
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
13
Sayı
3
Künye
Onur, B., Demirbas, H. B., & Gülmez, A. (2024). Role of biomarkers in community-acquired pneumonia management. Journal of Acute Disease, 13(3), 87-92. https://doi.org/10.4103/jad.jad_65_24
